Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK, Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA

Open source

DOI: 10.1136/bmjopen-2021-057663
Published: 2022 Jan 25
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2021-057663,
  title = {Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.},
  author = {Kok PS and Forde PM and Hughes B and Sun Z and Brown C and Ramalingam S and Cook A and Lesterhuis WJ and Yip S and O'Byrne K and Pavlakis N and Brahmer J and Anagnostou V and Ford K and Fitzpatrick K and Bricker A and Cummins MM and Stockler M and Nowak AK and Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA},
  year = {2022},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2021-057663},
  url = {https://doi.org/10.1136/bmjopen-2021-057663}
}

RIS

TY  - JOUR
TI  - Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
AU  - Kok PS
AU  - Forde PM
AU  - Hughes B
AU  - Sun Z
AU  - Brown C
AU  - Ramalingam S
AU  - Cook A
AU  - Lesterhuis WJ
AU  - Yip S
AU  - O'Byrne K
AU  - Pavlakis N
AU  - Brahmer J
AU  - Anagnostou V
AU  - Ford K
AU  - Fitzpatrick K
AU  - Bricker A
AU  - Cummins MM
AU  - Stockler M
AU  - Nowak AK
AU  - Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA
PY  - 2022
JO  - BMJ open
DO  - 10.1136/bmjopen-2021-057663
UR  - https://doi.org/10.1136/bmjopen-2021-057663
ER  -

APA

PS, K., PM, F., B, H., Z, S., C, B., S, R., A, C., WJ, L., S, Y., K, O., N, P., J, B., V, A., K, F., K, F., A, B., MM, C., M, S., AK, N., & USA, T. O. G. O. A. (. A. P. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.. BMJ open. https://doi.org/10.1136/bmjopen-2021-057663

Source records

pubmed · retrieved 2026-09-26T12:32:29.333Z